Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 346

1.

Prognosis and Chemosensitivity of Deficient MMR Phenotype in Patients with Metastatic Colorectal Cancer: an AGEO Retrospective Multicenter Study.

Tougeron D, Sueur B, Zaanan A, De La Fouchardiere C, Sefrioui D, Lecomte T, Aparicio T, Guetz GD, Artru P, Hautefeuille V, Coriat R, Moulin V, Locher C, Touchefeu Y, Lecaille C, Goujon G, Ferru A, Evrard C, Chautard R, Gentilhomme L, Vernerey D, Taieb J, André T, Henriques J, Cohen R; Association des Gastro-entérologues oncologues (AGEO).

Int J Cancer. 2020 Jan 22. doi: 10.1002/ijc.32879. [Epub ahead of print]

PMID:
31970760
2.

First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study.

Taieb J, Prager GW, Melisi D, Westphalen CB, D'Esquermes N, Ferreras A, Carrato A, Macarulla T.

ESMO Open. 2020 Jan;5(1). pii: e000587. doi: 10.1136/esmoopen-2019-000587.

3.

High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer.

Zaanan A, Calmel C, Henriques J, Svrcek M, Blons H, Desbois-Mouthon C, Merabtene F, Goumard C, Parc Y, Gayet B, Taieb J, Validire P, Louvet C, Fléjou JF, Le Bouc Y, Praz F.

Cell Oncol (Dordr). 2019 Dec 10. doi: 10.1007/s13402-019-00484-6. [Epub ahead of print]

PMID:
31823290
4.

Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study.

Reichling C, Taieb J, Derangere V, Klopfenstein Q, Le Malicot K, Gornet JM, Becheur H, Fein F, Cojocarasu O, Kaminsky MC, Lagasse JP, Luet D, Nguyen S, Etienne PL, Gasmi M, Vanoli A, Perrier H, Puig PL, Emile JF, Lepage C, Ghiringhelli F.

Gut. 2019 Nov 28. pii: gutjnl-2019-319292. doi: 10.1136/gutjnl-2019-319292. [Epub ahead of print]

5.

Radiation exposure during cardiac device implantation: Lessons learned from a multicenter registry.

Bru P, Dompnier A, Amara W, Haddad G, Galuscan G, Sagnol P, Steinbach M, Montagnier C, Taieb J, Beguec J, Milhem A; CNCH Cardiac Rhythm Group.

Pacing Clin Electrophysiol. 2020 Jan;43(1):87-92. doi: 10.1111/pace.13842. Epub 2019 Dec 11.

PMID:
31710385
6.

Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.

Auvray M, Tougeron D, Auclin E, Moulin V, Artru P, Hautefeuille V, Hammel P, Lecomte T, Locher C, Sickersen G, Coriat R, Lecaille C, Vernerey D, Taieb J, Pernot S.

Clin Colorectal Cancer. 2019 Sep 4. pii: S1533-0028(19)30090-8. doi: 10.1016/j.clcc.2019.08.003. [Epub ahead of print]

PMID:
31648924
7.

Arterial vascularization of the right colon with implications for surgery.

Bruzzi M, M'harzi L, Poghosyan T, Ben Abdallah I, Papadimitriou A, Ragot E, El Batti S, Balaya V, Taieb J, Chevallier JM, Douard R.

Surg Radiol Anat. 2019 Oct 21. doi: 10.1007/s00276-019-02359-9. [Epub ahead of print] Review.

PMID:
31637473
8.

Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.

Pointet AL, Tougeron D, Pernot S, Pozet A, Béchade D, Trouilloud I, Lourenco N, Hautefeuille V, Locher C, Williet N, Desrame J, Artru P, Soularue E, Le Roy B, Taieb J.

Clin Res Hepatol Gastroenterol. 2019 Oct 10. pii: S2210-7401(19)30193-7. doi: 10.1016/j.clinre.2019.08.009. [Epub ahead of print]

PMID:
31607641
9.

Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study.

Williet N, Saint A, Pointet AL, Tougeron D, Pernot S, Pozet A, Bechade D, Trouilloud I, Lourenco N, Hautefeuille V, Locher C, Desrame J, Artru P, Thirot Bidault A, Le Roy B, Pezet D, Phelip JM, Taieb J.

Therap Adv Gastroenterol. 2019 Sep 25;12:1756284819878660. doi: 10.1177/1756284819878660. eCollection 2019.

10.

Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.

Taieb J, Geissler M, Rivera F, Karthaus M, Wilson R, Loupakis F, Price T, Tracy M, Burdon P, Peeters M.

Clin Colorectal Cancer. 2019 Dec;18(4):245-256.e5. doi: 10.1016/j.clcc.2019.07.009. Epub 2019 Jul 29.

11.

Hereditary gastrointestinal cancers: why genetic counseling matters.

Taieb J.

Ann Oncol. 2019 Oct 1;30(10):1535-1536. doi: 10.1093/annonc/mdz254. No abstract available.

PMID:
31504125
12.

Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.

Moati E, Blons H, Taly V, Garlan F, Wang-Renault SF, Pietrasz D, Didelot A, Garrigou S, Saint A, Pernot S, Taieb J, Laurent-Puig P, Zaanan A.

Int J Cancer. 2019 Aug 31. doi: 10.1002/ijc.32657. [Epub ahead of print]

PMID:
31472013
13.

Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard's Tumor Regression Grade (TRG) in gastric adenocarcinoma.

Derieux S, Svrcek M, Manela S, Lagorce-Pages C, Berger A, André T, Taieb J, Paye F, Voron T.

Dig Liver Dis. 2020 Jan;52(1):107-114. doi: 10.1016/j.dld.2019.07.010. Epub 2019 Aug 16.

PMID:
31427088
14.

Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study.

Gallois C, Artru P, Lièvre A, Auclin E, Lecomte T, Locher C, Marthey L, Zaimi Y, Faroux R, Pernot S, Barret M, Taieb J.

Eur J Cancer. 2019 Sep;119:35-43. doi: 10.1016/j.ejca.2019.07.011. Epub 2019 Aug 12.

PMID:
31415985
15.

The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer.

Le Corre D, Ghazi A, Balogoun R, Pilati C, Aparicio T, Martin-Lannerée S, Marisa L, Djouadi F, Poindessous V, Crozet C, Emile JF, Mulot C, Le Malicot K, Boige V, Blons H, de Reynies A, Taieb J, Ghiringhelli F, Bennouna J, Launay JM, Laurent-Puig P, Mouillet-Richard S.

EBioMedicine. 2019 Aug;46:94-104. doi: 10.1016/j.ebiom.2019.07.036. Epub 2019 Jul 31.

16.

Ampullary carcinoma prognostic markers.

Perkins G, Laurent-Puig P, Taieb J.

Oncotarget. 2019 Jul 16;10(44):4509-4510. doi: 10.18632/oncotarget.27067. eCollection 2019 Jul 16. No abstract available.

17.

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22).

Karoui M, Rullier A, Piessen G, Legoux JL, Barbier E, De Chaisemartin C, Lecaille C, Bouche O, Ammarguellat H, Brunetti F, Prudhomme M, Regimbeau JM, Glehen O, Lievre A, Portier G, Hartwig J, Goujon G, Romain B, Lepage C, Taieb J; for PRODIGE 22 investigators/Collaborators.

Ann Surg. 2019 Jul 6. doi: 10.1097/SLA.0000000000003454. [Epub ahead of print]

PMID:
31356278
18.

Exploring the best treatment options for BRAF-mutant metastatic colon cancer.

Taieb J, Lapeyre-Prost A, Laurent Puig P, Zaanan A.

Br J Cancer. 2019 Sep;121(6):434-442. doi: 10.1038/s41416-019-0526-2. Epub 2019 Jul 29. Review.

PMID:
31353365
19.

The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.

Taieb J, Jung A, Sartore-Bianchi A, Peeters M, Seligmann J, Zaanan A, Burdon P, Montagut C, Laurent-Puig P.

Drugs. 2019 Sep;79(13):1375-1394. doi: 10.1007/s40265-019-01165-2. Review.

20.

BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study.

Mas L, Bachet JB, Taly V, Bouché O, Taieb J, Cohen R, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Blons H, Vernerey D, Laurent-Puig P.

Cancers (Basel). 2019 Jul 17;11(7). pii: E998. doi: 10.3390/cancers11070998.

21.

Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.

Charton E, Bachet JB, Hammel P, Desramé J, Chibaudel B, Cohen R, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Guerin-Meyer V, Taieb J, Volet J, Louvet C, Anota A, Bonnetain F.

Cancer Med. 2019 Sep;8(11):5079-5088. doi: 10.1002/cam4.2311. Epub 2019 Jul 17.

22.

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.

Auclin E, André T, Taieb J, Banzi M, Van Laethem JL, Tabernero J, Hickish T, de Gramont A, Vernerey D.

Br J Cancer. 2019 Aug;121(4):312-317. doi: 10.1038/s41416-019-0521-7. Epub 2019 Jul 12.

PMID:
31296923
23.

Factors associated with anal cancer screening uptake in men who have sex with men living with HIV: a cross-sectional study.

Vanhaesebrouck A, Pernot S, Pavie J, Lucas ML, Collias L, Péré H, Taieb J, Weiss L, Grabar S.

Eur J Cancer Prev. 2020 Jan;29(1):1-6. doi: 10.1097/CEJ.0000000000000507.

PMID:
31283539
24.

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.

Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, André T.

Ann Oncol. 2019 Sep 1;30(9):1466-1471. doi: 10.1093/annonc/mdz208.

PMID:
31268130
25.

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.

Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E, Penault-Llorca F, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Baptiste Bachet J, Borg C, Boige V, Voron T, Stanbury T, Tartour E, Gourgou S, Malka D, Taieb J.

Gastric Cancer. 2020 Jan;23(1):73-81. doi: 10.1007/s10120-019-00983-3. Epub 2019 Jul 2.

PMID:
31267360
26.

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials.

Auclin E, Taieb J, Lepage C, Aparicio T, Faroux R, Mini E, Folprecht G, Salazar R, Benetkiewicz M, Banzi M, Louvet C, Van Laethem JL, Tabernero J, Hickish T, de Gramont A, André T, Vernerey D.

Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1153-1161. doi: 10.1158/1055-9965.EPI-18-0867.

PMID:
31263053
27.

Management of acute cardiac tamponade by direct autologous blood transfusion in interventional electrophysiology.

Beyls C, Hermida A, Duchateau J, Maury P, Taieb J, Laurent G, Kubala M, Ben Amar A, Sacher F, Jais P, Hermida JS.

J Cardiovasc Electrophysiol. 2019 Aug;30(8):1287-1293. doi: 10.1111/jce.14050. Epub 2019 Jul 22.

PMID:
31240813
28.

Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.

Bruzzi M, Auclin E, Lo Dico R, Voron T, Karoui M, Espin E, Cianchi F, Weitz J, Buggenhout A, Malafosse R, Denimal F, Le Malicot K, Vernerey D, Douard R, Emile JF, Lepage C, Laurent-Puig P, Taieb J.

Ann Surg Oncol. 2019 Oct;26(11):3561-3567. doi: 10.1245/s10434-019-07513-6. Epub 2019 Jun 17.

PMID:
31209667
29.

Prediction of ventricular arrhythmias in patients with a spontaneous Brugada type 1 pattern: the key is in the electrocardiogram.

Delinière A, Baranchuk A, Giai J, Bessiere F, Maucort-Boulch D, Defaye P, Marijon E, Le Vavasseur O, Dobreanu D, Scridon A, Da Costa A, Delacrétaz E, Kouakam C, Eschalier R, Extramiana F, Leenhardt A, Burri H, Winum PF, Taieb J, Bouet J, Fauvernier M, Rosianu H, Carabelli A, Duband B, Chevalier P.

Europace. 2019 Sep 1;21(9):1400-1409. doi: 10.1093/europace/euz156.

PMID:
31177270
30.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, de la Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J.

Eur J Cancer. 2019 Jul;115:97-106. doi: 10.1016/j.ejca.2019.04.020. Epub 2019 May 23.

PMID:
31129386
31.

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.

Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Barbier E, Boige V, Taieb J, Bouché O, François E, Phelip JM, Borel C, Faroux R, Seitz JF, Jacquot S, Ben Abdelghani M, Khemissa-Akouz F, Genet D, Jouve JL, Rinaldi Y, Desseigne F, Texereau P, Suc E, Lepage C, Aparicio T, Hoeffel C; PRODIGE 9 Investigators and PRODIGE 20 Investigators.

Gut. 2019 May 17. pii: gutjnl-2018-316407. doi: 10.1136/gutjnl-2018-316407. [Epub ahead of print]

PMID:
31101691
32.

Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.

Kourie H, Auclin E, Cunha AS, Gaujoux S, Bruzzi M, Sauvanet A, Lourenco N, Trouilloud I, Louafi S, El-Hajjar A, Vaillant JC, Smith D, Touchefeu Y, Bachet JB, Pietrasz D, Taieb J.

Clin Res Hepatol Gastroenterol. 2019 Nov;43(6):663-668. doi: 10.1016/j.clinre.2019.03.007. Epub 2019 Apr 24.

PMID:
31029644
33.

How is Contact Force implemented in routine clinical practice? Results from a French National and Monaco Survey.

Bun SS, Lațcu DG, Taghji P, Anselme F, Boveda S, Cebron JP, Defaye P, Deharo JC, Fauchier L, Gandjbakhch E, Gras D, Klug D, Mansourati J, Marijon E, Maury JP, Squara F, Saoudi N, Taïeb J.

J Arrhythm. 2019 Feb 15;35(2):238-243. doi: 10.1002/joa3.12165. eCollection 2019 Apr.

34.

Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data.

Boulet S, Ursino M, Thall P, Landi B, Lepère C, Pernot S, Burgun A, Taieb J, Zaanan A, Zohar S, Jannot AS.

Stat Methods Med Res. 2019 Apr 9:962280219841082. doi: 10.1177/0962280219841082. [Epub ahead of print]

PMID:
30963815
35.

Reply to the letter about the position paper concerning the competence, performance and environment required in the practice of complex ablation procedures.

Maury P, Defaye P, Klug D, Alonso C, Anselme F, Fauchier L, Gandjbakhch E, Gras D, Hermida JS, Laurent G, Mansourati J, Marijon E, Sacher F, Taieb J, Boveda S, Piot O, Sadoul N; Working Group on Pacing, Electrophysiology of the French Society of Cardiology.

Arch Cardiovasc Dis. 2019 Apr;112(4):290-291. doi: 10.1016/j.acvd.2018.11.012. Epub 2019 Mar 18. No abstract available.

PMID:
30898475
36.

How to better select patients with advanced gastric cancer for immunotherapy.

Zaanan A, Taieb J.

Transl Gastroenterol Hepatol. 2019 Jan 31;4:6. doi: 10.21037/tgh.2019.01.06. eCollection 2019. No abstract available.

37.

How best to treat older patients with metastatic colorectal cancer?

Taieb J.

Lancet Gastroenterol Hepatol. 2019 May;4(5):331-333. doi: 10.1016/S2468-1253(19)30076-7. Epub 2019 Mar 7. No abstract available.

PMID:
30852135
38.

Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives.

Taieb J, André T, Auclin E.

Cancer Treat Rev. 2019 May;75:1-11. doi: 10.1016/j.ctrv.2019.02.002. Epub 2019 Feb 26. Review.

PMID:
30849607
39.

Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study.

Perkins G, Svrcek M, Bouchet-Doumenq C, Voron T, Colussi O, Debove C, Merabtene F, Dumont S, Sauvanet A, Hammel P, Cros J, André T, Bachet JB, Bardier A, Douard R, Meatchi T, Peschaud F, Emile JF, Cojean-Zelek I, Laurent-Puig P, Taieb J.

Br J Cancer. 2019 Apr;120(7):697-702. doi: 10.1038/s41416-019-0415-8. Epub 2019 Mar 6.

PMID:
30837681
40.

Relationship between vitamin D status in pregnancy and the risk for preeclampsia: A nested case-control study.

Benachi A, Baptiste A, Taieb J, Tsatsaris V, Guibourdenche J, Senat MV, Haidar H, Jani J, Guizani M, Jouannic JM, Haguet MC, Winer N, Masson D, Courbebaisse M, Elie C, Souberbielle JC.

Clin Nutr. 2019 Feb 15. pii: S0261-5614(19)30069-X. doi: 10.1016/j.clnu.2019.02.015. [Epub ahead of print]

PMID:
30799191
41.

Occurrence of significant long PR intervals in patients implanted for sinus node dysfunction and monitored with SafeR™: The PRECISE study.

Taieb J, Le Franc P, Khattar P, Moubarak G, Gorka H, Godenir JP, Deutsch P, Degand B, Al Daoud A, Elkaim JP, Elbaz N, Merlo S, Lellouche N.

Arch Cardiovasc Dis. 2019 Mar;112(3):153-161. doi: 10.1016/j.acvd.2018.09.005. Epub 2018 Dec 26.

42.

[Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?]

Zaanan A, Taieb J.

Bull Cancer. 2019 Feb;106(2):129-136. doi: 10.1016/j.bulcan.2018.10.011. Epub 2018 Dec 4. Review. French.

PMID:
30527814
43.

Inter-mesenteric connections between the superior and inferior mesenteric arteries for left colonic vascularization: implications for colorectal surgery.

Bruzzi M, M'harzi L, El Batti S, Ghazaleh RA, Taieb J, Poghosyan T, Berger A, Chevallier JM, Douard R.

Surg Radiol Anat. 2019 Mar;41(3):255-264. doi: 10.1007/s00276-018-2139-5. Epub 2018 Nov 26.

PMID:
30478643
44.

Author Correction: Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer.

Bibault JE, Giraud P, Housset M, Durdux C, Taieb J, Berger A, Coriat R, Chaussade S, Dousset B, Nordlinger B, Burgun A.

Sci Rep. 2018 Nov 12;8(1):16914. doi: 10.1038/s41598-018-35359-7.

45.

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.

Bennouna J, André T, Campion L, Hiret S, Miglianico L, Mineur L, Touchefeu Y, Artru P, Asmis T, Bouché O, Borde F, Kavan P, Lam YH, Rajpar LS, Emile JF, Jouffroy C, Gill S, Taïeb J.

Clin Colorectal Cancer. 2019 Mar;18(1):e69-e73. doi: 10.1016/j.clcc.2018.09.011. Epub 2018 Oct 19.

PMID:
30415988
46.

Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design.

Moehler M, Ryu MH, Dvorkin M, Lee KW, Coşkun HŞ, Wong R, Chung HC, Poltoratsky A, Tsuji A, Yen CJ, Muntean AS, Le Sourd S, Vaccaro GM, Overton L, Boku N, Wainberg ZA, Patel M, Sharma M, Xiong H, Conti I, Taieb J, Bang YJ.

Future Oncol. 2019 Feb;15(6):567-577. doi: 10.2217/fon-2018-0668. Epub 2018 Oct 31.

47.

How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort.

Pietrasz D, Turrini O, Vendrely V, Simon JM, Hentic O, Coriat R, Portales F, Le Roy B, Taieb J, Regenet N, Goere D, Artru P, Vaillant JC, Huguet F, Laurent C, Sauvanet A, Delpero JR, Bachet JB, Sa Cunha A.

Ann Surg Oncol. 2019 Jan;26(1):109-117. doi: 10.1245/s10434-018-6931-6. Epub 2018 Oct 25.

PMID:
30362063
48.

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.

Bachet JB, Lucidarme O, Levache CB, Barbier E, Raoul JL, Lecomte T, Desauw C, Brocard F, Pernot S, Breysacher G, Lagasse JP, Di Fiore F, Etienne PL, Dupuis OJM, Aleba A, Lepage C, Taieb J; for FFCD 1102 investigators.

Eur J Cancer. 2018 Nov;104:108-116. doi: 10.1016/j.ejca.2018.09.006. Epub 2018 Oct 18.

PMID:
30343254
49.

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.

Yoshino T, Portnoy DC, Obermannová R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, García-Alfonso P, Cohn AL, Van Cutsem E, Yamazaki K, Lonardi S, Muro K, Kim TW, Yamaguchi K, Grothey A, O'Connor J, Taieb J, Wijayawardana SR, Hozak RR, Nasroulah F, Tabernero J.

Ann Oncol. 2019 Jan 1;30(1):124-131. doi: 10.1093/annonc/mdy461.

50.

Noninvasive detection of atrial fibrillation in cryptogenic stroke: Contribution of a new e-cardiology device.

Tarlet JM, Taieb J, Di Legge S, Boccara G, Coulon D, Guenoun M.

HeartRhythm Case Rep. 2018 Jun 22;4(9):412-414. doi: 10.1016/j.hrcr.2018.06.006. eCollection 2018 Sep. No abstract available.

Supplemental Content

Support Center